The merger issue somewhat clouds some other concerning issues though.
1. Our failure to license Vapendavir;
2. the failure of our RSV candidate;
3. the delay in starting Lani Ph2 trial.
Maybe our shareprice should be a dollar in Aussie terms but it doesnt deserve to be rocketing either.
Forget about the merger. Based on near term fundamentals, why would anyone need to rush into buying Bota?
up 16c, page-59
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)